Kornimate/medical-research-clean huggingface dataset:
study on appropriate technology of standardized diagnosis and treatment for diabetic patients with pulmonary infections

Conditions: Diabetes Mellitus; Pulmonary Infection

Summary: focusing on patients with diabetes complicated with pulmonary infection, the purpose of this study is: 1) to identify the epidemiology, etiologic spectrum and status of diagnosis and treatment; 2) to develop a symptom score scale , clarify the risk factors and create a precise warning model; 3) to develop a rapid detection of pathogen of lower respiratory infection, to establish clinical pathways of early diagnosis and treatment of diabetes complicated with pulmonary infections (including bacterial, tuberculosis and fungal infections) and then make an application in clinic.

investigators perform a observational study on 6000 patients with diabetes, among which 200 patients with pulmonary infection are included in a retrospective study and 100 patients go through metabolomics research. all patients receive clinical questionnaires, laboratory examinations and pulmonary function tests. investigators study on pathogen distribution and infection ratio of patients above depending on follow-up survey. 1:1 nested case-control study is carried out involving 100 cases from pulmonary-infected group paired with 100 control cases matched for gender, age and fasting blood-glucose. the final purpose is to create a precise warning model in order to develop a rapid detection of pathogen of lower respiratory infection in diabetes patients. now investigators wish to register this study to do a further research, in order to improve the early diagnosis of diabetes complicated with pulmonary infection and to reduce the mortality.

Eligibility criteria:
inclusion criteria: * diagnosis by pathogen examination: positive * diagnosis through x-ray or ct: characteristic features of pulmonary infection * diagnosis through guideline of diabetes or history of diagnosed diabetes * age 40-70 years exclusion criteria: * irregular follow-up and lost follow-up * withdraw from the study for any reason

Keywords: early warning model clinical pathway diabetes pulmonary infection
clinical trail of repetitive transcranial magnetic stimulation (rtms) in the treatment of upper limb bradykinesia in parkinson' disease' patients

Conditions: Parkinson&#39;s Disease (PD); Bradykinesia; Upper Limb Function

Summary: a randomized, double-blind, sham-controlled unicenter clinical trial was used to investigate the effectiveness and neural mechanism of high-frequency repetitive transcranial magnetic stimulation in the treatment of upper limb bradykinesia in patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: * hoehn and yahr (hy) stage 1-2 * able to understand and cooperate with the study * predominantly characterized by bradykinesia * onset on the left side exclusion criteria: * contraindications for tms including dbs surgery, ventriculoperitoneal shunt, etc * other neurological disorders * significant resting tremor, with mds-updrs-iii tremor score ≥3 * resting threshold cannot be measured * received other tms treatments within the last 3 months
study on the effectiveness and feasibility of prone position ventilation technology in congenital heart disease

Conditions: Investigative Techniques

Summary: the purpose of this study was to compare the effects of conventional lying position and prone position ventilation on infants with acute lung injury after surgery for congenital heart disease. to explore the effectiveness and feasibility of prone position ventilation for children with acute lung injury after congenital heart disease surgery.

the prone position has been used to treat severe hypoxemia in patients with acute respiration dysfunction syndrome (ards) since the 1970s, and it has significant effectiveness in improving gas exchange. acute lung injury (ali) is a common complication after congenital heart disease. the clinical manifestation is refractory hypoxemia. at present, mechanical ventilation is one of the main methods for the treatment of acute lung injury-induced respiratory distress syndrome. prone position ventilation refers to placing the patient in the prone position during mechanical ventilation to expand the lungs in the atelectasis area and improve the ratio of lung ventilation and perfusion. prone position ventilation technology as an important lung protection ventilation strategy has been widely used clinically at home and abroad. compared with adults, children are more convenient and easy to implement. due to the exact mechanism of improving oxygenation function, the current domestic and foreign development of pediatric prone ventilation technology is mainly focused on children with ards. there are few studies on high-quality application effects after pediatric cardiac surgery, and almost no research has been carried out, especially for pediatric heart the indications for the implementation of the prone position after the disease surgery, the specific standardized process including the position angle, the prone duration plan, etc. all need to be studied. therefore, there is an urgent need to develop prone position ventilation technology for critically ill children with congenital heart disease after surgery to reduce postoperative pulmonary complications and shorten the time of mechanical ventilation.

Eligibility criteria:
inclusion criteria: * patients with lung injury after congenital heart disease or chest x-ray ct suggest that pulmonary complications need to strengthen body drainage * establish artificial airway, such as tracheal intubation * children aged 0-12 months * stable hemodynamics, more than 72 hours after surgery * informed consent of family members exclusion criteria: * unstable hemodynamics, severe hypotension, ventricular arrhythmia * intracranial hypertension * active acute bleeding * spinal injuries and untreated unstable fractures, orthopedic surgery or recent abdominal surgery * facial trauma * severe pneumothorax * delayed chest closure and wound infection, children who need to be immobilized
open label long-term safety study of certolizumab pegol (czp) for patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the primary purpose of this study is to obtain long-term safety data with czp in patients with rheumatoid arthritis (ra). additional objectives are to assess the dose and type of arthritis medication(s) utilized by patients, and to assess the long-term impact of czp on physical function. treatment will continue up to approval of a marketing application for this product.


Eligibility criteria:
inclusion criteria: * participation in czp trial c87014 or c87011 * if female and of childbearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception since her last menses, will use adequate contraception during the study and for 12 weeks after the last dose of study drug (or longer if required by local regulations), is not lactating, and has had a negative urine pregnancy test on the day of receiving the first dose of study drug * must have provided written informed consent before undergoing any study procedures exclusion criteria: * history (hx) of chronic infection, serious or life-threatening infection - (including herpes zoster) within 6 months prior, or any current symptom indicating infection * current or recent hx of severe, progressive and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease * any finding indicative of tuberculosis at end of previous study * known hiv infection * persistently abnormal ast (aspartate aminotransferase) or alt (alanine aminotransferase) results (\> 2 times upper limit of normal) * hemoglobin (hgb) levels \< 9 g/dl or hematocrit \< 30 % * total white blood cell (wbc) count of \< 3.0 x 100/l (\< 3000/mm\^3) * platelet count \< 100 x 100 l (100,000/mm\^3) * serum creatinine \> 1.5 times upper limit of normal based on patient age and sex * receipt of any biological therapies for ra in 6 months prior to study entry or any prior treatment (tx) with tumor necrosis factor (tnf) blocking agent (excluding cdp870) * receipt of any vaccination (live, attenuated or killed) in 8 weeks prior to baseline * any other condition which the principal investigator judges would make patient unsuitable for study participation

Keywords: rheumatoid arthritis america college of rheumatology disease modifying anti-rheumatic drug certolizumab pegol (cdp870)
a safety and immunogenicity trial with an adjuvanted tuberculosis(tb) subunit vaccine

Conditions: Tuberculosis

Summary: the purpose of this study is to evaluate the safety profile of an adjuvanted tb subunit vaccine administered at 0 and 2 months in healthy bcg-unvaccinated volunteers with no prior history of tb disease or known prior exposure to tb


Eligibility criteria:
inclusion criteria: * male * healthy based on medical examination/history at the inclusion * age between 18 and 55 years * signed informed consent * prepared to grant authorized persons access to the medical records * the volunteer is likely to comply with instructions exclusion criteria: * known exposure to tb before (or expected during) the trial * prior bcg vaccination * granulomatous disease (by chest x-ray, autoimmune screen) * vaccinated with live vaccine 3 months before first vaccination * administration of immune modulating drugs (steroids, immunosuppressive drugs or immunoglobulins) 3 months before the first vaccination * hbv, hcv or hiv sero-positive (hbsag, hbsab, hbc total and igm ab and hcv, hiv-1 and hiv2 ab) * participation in other clinical trials * positive mantoux or quantiferon-tb gold * known hypersensitivity to any of the vaccine components * laboratory parameters outside of normal ranges considered clinically relevant

Keywords: tuberculosis vaccine ag85b esat-6 ic31
cognitive dysfunction after aneurysmal subarachnoid haemorrhage

Conditions: Cognitive Dysfunction

Summary: this is a longitudinal, multi-center, prospective study of aneurysmal subarachnoid haemorrhage patients in neurosurgical units in hong kong.

the investigators aim to recruit a total of 240 aneurysmal subarachnoid haemorrhage patients. the schedule for neuropsychological and functional assessments will be phased in at the second to third week, the third month, and the twelve months after the initial haemorrhage.

Eligibility criteria:
inclusion criteria 1. spontaneous subarachnoid haemorrhage with intracranial aneurysms as aetiology 2. admission within 96 hours of ictus 3. aged between 21 and 75 years 4. a speaker of chinese (mandarin or cantonese) 5. informed consent from patients or their legally acceptable representatives exclusion criteria 1. history of previous cerebrovascular disease or neurological disease other than intracranial aneurysm 2. history of neurosurgical operation prior to ictus

Keywords: cognition, subarachnoid hemorrhage.
physical activity level in patients with osas during covid-19 pandemic

Conditions: Obstructive Sleep Apnea-hypopnea Syndrome

Summary: as long as the people stay at home because of the covid 19 outbreak, the investigators assume that the sleep quality of ouas patients, like everyone else, and the sleep quality of covid-19 outbreak are reduced due to anxiety and anxiety in people. in addition, we assume that sleep quality and physical activity level are related to health literacy level and fear of movement (kinesiophobia). in this study; the investigators aimed to determine how patients are affected by this process by evaluating sleep quality, physical activity, fear of movement and health literacy in osas patients during our stay in the covid-19 outbreak.

research ahi evren chest cardiovascular surgery training research hospital will be performed in patients between the ages of 18-70 years, diagnosed with osas in the sleep laboratory. sleep quality, physical activity, fear of movement and health literacy will be evaluated in osas patients. evaluations will be made by phone in order for the study to be strong, it will be tried to reach the maximum patient that can be taken between june 2020 and october 2020.

Eligibility criteria:
inclusion criteria: 1. having been diagnosed with osas and disease severity determined, 2. being between the age of 19-70, 3. body mass index \<40 kg / m2 4. volunteering to participate in the research, 5. not having a mental problem that will hinder the cooperation. exclusion criteria: 1. to have advanced orthopedic, neurological and cardiovascular disease, 2. having a cognitive problem,

Keywords: physical activity covid-19 sleep quality
ultrasound imaging of core muscles activity in multiparous women with vaginal laxity: a cross-sectional study

Conditions: Vaginal Laxity

Summary: this study aims to compare the ultrasound imaging of core muscles activity in multiparous women with vaginal laxity versus normal controls.

vaginal laxity is characterized by the loss of elasticity in the vaginal structure and vaginal looseness, which leads to symptoms including sexual dysfunction, dyspareunia, chronic pelvic pain, and urinary incontinence. it is a symptom of pelvic floor dysfunction. its mechanisms are not well understood and it is usually worse in women with multiparity. since the pelvic floor muscles (pfms) are one of the core muscles that play a critical role in lumbopelvic stability, their impairment may affect the lumbopelvic area and the activity of other core muscles, like the transverse abdominis, lumbar multifidus, and diaphragm. therefore, this study aims to compare the ultrasound imaging of core muscles activity in multiparous women with vaginal laxity versus normal controls.

Eligibility criteria:
inclusion criteria: 1. the participants' age range from 35 to 45 years 2. their body mass index is 25-30 kg/m2, 3. the number of normal deliveries ≤ three times, 4. having a regular menstruation. 5. they participate in the study after at least two years from their last delivery. exclusion criteria: 1. prior history of disc prolapse and sacroiliac joints, symphysis pubic joint as well as lower limb problems, leg length discrepancy, and diastasis recti. 2. surgery related to the spine, abdomen or pelvis. 3. genital prolapse, urinary tract infection, and intrauterine device. 4. diabetes, chest and/or cardiac disease. 5. using any drugs for sexual dysfunction.

Keywords: ultrasound imaging core muscles activity multiparous women vaginal laxity
efficacy and safety of tj-100 in the treatment of chronic constipation

Conditions: Chronic Constipation

Summary: tj-100, a japanese herbal medicine, is clinically effective in postoperative ileus. so it may activate bowel movement. this study will test the efficacy and safety of tj-100 in the treatment of patients with chronic constipation.


Eligibility criteria:
inclusion criteria: * chronic constipation defined as less than 3 spontaneous bowel movement frequencies per week * had symptoms of abdominal bloating or discomfort exclusion criteria: * mechanical bowel obstruction * clinically systemic disease-induced constipation * pregnancy

Keywords: constipation
testing a cognitive behavioral model for reducing dyspnea in patients with lung cancer

Conditions: Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma

Summary: this trial studies the effect of a form of cognitive-behavioral therapy, take a breath, on reducing the intensity and frequency of dyspnea (difficulty breathing) in patients with lung cancer. take a breath consists of individual therapy sessions that educate patients on dyspnea and provides coping strategies.

primary objective: i. to determine the acceptability (based on patient satisfaction), tolerability (based on rate of symptom exacerbation from pre- to post-treatment), and feasibility (based on number of patients agreeing to be participate, adherence rate, and retention rate of treatment) of take a breath (tab), a skills-based cognitive-behavioral treatment lasting 4 weekly hour-long sessions targeting dyspnea and related distress and impairment, in adults with lung cancer (n=40). secondary objectives: i. to provide preliminary data on the effectiveness of tab on dyspnea and related distress and impairment. ii. to test cognitive-behavioral variables (physical symptoms, thoughts, behaviors, and emotions) as predictors of dyspnea severity and anxiety sensitivity as a moderator. outline: patients are randomized to 1 of 2 arms. arm i: patients participate in 4 weekly tab in-person or video conference sessions over 1 hour each that provide them with skills to cope with their dyspnea. patients also receive treatment handouts, a compact disk (cd) with an audio file with instructions for progressive muscle relaxation, and a pulse oximeter. patients may receive additional support calls over 10-15 minutes from the tab provider within 1 week following each session. arm ii: patients receive usual management of dyspnea from the treating physician. after completion of study, patients are followed up at 1 month.

Eligibility criteria:
inclusion criteria: * diagnosed with non-small cell lung cancer (nsclc) or small cell lung cancer (sclc) * currently experiencing dyspnea as defined by a score \>= 1 on the american thoracic society (ats) dyspnea questionnaire within 3 weeks of enrollment * seeking medical oncology care and treatment at the ohio state university comprehensive cancer center (osuccc) thoracic oncology clinic * ability to understand and willingness to sign an informed consent document exclusion criteria: * presence of other serious comorbidities that would interfere with patients' study participation (e.g., serious mental illness, heart disease) as determined by the treating oncologist * life expectancy \< 2 months * history of surgery for lung cancer
expanded access program of ruxolitinib for the emergency treatment of cytokine storm from covid-19 infection

Conditions: COVID-19

Summary: to provide ruxolitinib through an expanded access program for the treatment of cytokine storm due to covid-19 in the united states to patients who are eligible but not able to be hospitalized or who are hospitalized with a clinical diagnosis and/or positive test for sard-cov-2 infection.


Eligibility criteria:
inclusion criteria: * male or female, 12 years of age or older. * clinical diagnosis of covid-19 and/or locally accepted positive test; if feasible, swab should be taken and saved for quantitative testing to determine viral load. * disease severity making the patient eligible for hospitalization (whether or not hospitalization is available), with evidence of cytokine storm as determined by the treating physician. manifestations of cytokine storm can include the following: * severe shortness of breath (respiratory rate \> 24 breaths/minute). * spo2 of \< 90% on ambient air. * need for invasive or noninvasive mechanical ventilation. * acute respiratory distress syndrome. * multiple organ failure. * be willing to avoid pregnancy or fathering children * able to provide written informed consent, consent from the patient's legally authorized representative, and/or assent from the patient, parent, or guardian. exclusion criteria: * patients, patient's legally authorized representative, or legal guardians unable to review and sign icf. * females who are pregnant or breastfeeding, and males and females who cannot comply with requirements to avoid fathering a child or becoming pregnant. * patients with inadequate liver function (alt above 4 × uln or direct bilirubin 4 × uln and the laboratory abnormalities are considered to be due to underlying liver dysfunction). * patients with platelet counts \< 50 × 109 /l * any underlying or current medical or psychiatric condition that, in the opinion of the treating physician, would place the patient at an unacceptable risk if he or she were to participate in the program. * previous allergic reactions to jak inhibitors or excipients. * concomitant use of any other jak inhibitor. * is eligible or able to access ruxolitinib through an incyte-sponsored clinical study or is eligible for another therapeutic clinical trial for cytokine storm at the treating institution..

Keywords: sars-cov-2 cytokine storm ruxolitinib
a study of zolpidem tartrate sublingual tablet in adult patients with insomnia

Conditions: Insomnia

Summary: the purpose of the study is to evaluate sleep onset following administration of zolpidem tartrate sublingual tablet (intermezzo) versus placebo in adult insomnia patients.


Eligibility criteria:
inclusion criteria: * adults with history of sleeplessness exclusion criteria: * allergic to investigational drug * any conditions and medications that may interfere with study drug evaluation

Keywords: insomnia
rural andhra pradesh cardiovascular prevention study (rapcaps)

Conditions: Myocardial Infarction; Angina Pectoris; Cerebrovascular Accidents; Diabetes Mellitus

Summary: this study will evaluate the effectiveness of a novel cardiovascular disease prevention program designed for delivery through existing primary health care services in rural villages in andhra pradesh. the primary aim is to increase the number of high-risk individuals in the population that are appropriately managed with proven, low-cost preventive interventions. the corresponding null hypothesis is therefore that the prevention program will result in no change in the proportion of high-risk individuals identified and treated in villages assigned to intervention compared with those villages assigned to control.

study type this project is a community intervention study that will use a large-scale, cluster-randomised design to compare the management of individuals at high cardiovascular risk in villages assigned to receive the cardiovascular prevention program (intervention) and villages assigned to continue usual practices (control). the definition of high-risk for treatment is based on an established history of previous vascular disease -heart attack or stroke- known hypertension or systolic blood pressure \> 160mmhg, or the presence of other risk factors such as smoking, high blood pressure, obesity, older age and family history which combined would result in a very high level of risk. intervention program to be evaluated the program to be evaluated comprises: (1) simple strategies designed to facilitate the opportunistic identification of high-risk individuals, (2) clinical algorithms for the implementation of proven preventive interventions based on world health organisation recommendations (3) a health promotion campaign designed to aid self-identification and self-referral of high-risk people and (4) simple, structured education programs to assist patients to comply with their treatment. data collection data to be collected will comprise an interviewer administered questionnaire with demographic details, basic medical history, cardiovascular risk factors, previous cardiovascular disease and any current treatments. this will be followed by a brief physical examination including measurement of blood pressure, heart rate, weight, height, waist and hip circumferences. urine will be tested using a dipstick in all and all will have a fasting blood glucose assay. fasting venous blood samples will be collected for assay of cholesterol, glucose and creatinine from a sample of 1,000.

Eligibility criteria:
inclusion criteria: * age 30 years and above * personal history of heart attack or stroke * presence of other cardiovascular risk factors such as smoking, overweight, diabetes exclusion criteria: * mental disability * not living in the study area

Keywords: myocardial infarction angina pectoris cerebrovascular accident diabetes mellitus cluster randomized design community-based intervention trial primary healthcare intervention lifestyle advice